Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine-Reference-Cited by-同舟云学术

Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine

Published:2015-12-17 Issue:7 Volume:41 Page:1917-1928
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Schmidt Heath D,Mietlicki-Baase Elizabeth G,Ige Kelsey Y,Maurer John J,Reiner David J,Zimmer Derek J,Van Nest Duncan S,Guercio Leonardo A,Wimmer Mathieu E,Olivos Diana R,De Jonghe Bart C,Hayes Matthew R

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/npp2015362.pdf

Reference56 articles.

1. Alhadeff AL, Rupprecht LE, Hayes MR (2012). GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 153: 647–658.

2. Arnold JM, Roberts DC (1997). A critique of fixed and progressive ratio schedules used to examine the neural substrates of drug reinforcement. Pharmacol Biochem Behav 57: 441–447.

3. Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ (2011). Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 31: 3904–3913.

4. Buffalari DM, Rinaman L (2014). Cocaine self-administration and extinction alter medullary noradrenergic and limbic forebrain cFos responses to acute, noncontingent cocaine injections in adult rats. Neuroscience 281C: 241–250.

5. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH et al (2009). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39–47.

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target;Pharmacological Research;2024-09

2. The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients;Journal of Addiction Medicine;2024-08-02

3. Dissociable hindbrain GLP1R circuits for satiety and aversion;Nature;2024-07-10

4. Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence;Physiology & Behavior;2024-07

5. Compensatory enhancement of input maintains aversive dopaminergic reinforcement in hungry Drosophila;Neuron;2024-07